# Adjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World Study

> **NCT07640048** · — · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Intrahepatic Cholangiocarcinoma (Icc)

## Interventions

- **DRUG:** Adebrelimab
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DRUG:** S-1
- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT07640048
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-04
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07640048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07640048, "Adjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World Study". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07640048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*